The 'partial thromboplastin time' (PTT) or 'activated partial thromboplastin time' ('aPTT' or 'APTT') is a performance indicator measuring the efficacy of both the "intrinsic" (now referred to as the ''contact activation pathway'') and the common
coagulation pathways. Apart from detecting abnormalities in blood clotting, it is also used to monitor the treatment effects with
heparin, a major
anticoagulant.
Methodology
Blood is collected, by a
phlebotomist, with
oxalate or
citrate which arrest coagulation by binding calcium. This specimen is delivered to the laboratory. In order to activate the intrinsic pathway,
phospholipid, an activator (such as
silica,
celite,
kaolin,
ellagic acid), and
calcium (to reverse the anticoagulant effect of the oxalate) are mixed into the
plasma sample . The time is measured until a
thrombus (clot) forms. This testing is performed by a
medical technologist.
The test is termed "partial" due to the absence of
tissue factor from the reaction mixture.
Interpretation
Values below 25
seconds or over 39 s (depending on local normal ranges) are generally abnormal. Shortening of the PTT has little clinical relevance. Prolonged APTT may indicate:
★ use of
heparin (or contamination of the sample)
★
antiphospholipid antibody (especially
lupus anticoagulant, which paradoxically increases propensity to thrombosis)
★ coagulation factor deficiency (e.g.
hemophilia)
To distinguish the above causes, ''mixing studies'' are performed, in which the patient's plasma is mixed (initially at a 50:50 dilution) with normal plasma. If the abnormality does not disappear, the sample is said to contain an "inhibitor" (either heparin, antiphospholipid antibodies or coagulation factor specific inhibitors), while if it does correct a factor deficiency is more likely. Deficiencies of
factors VIII,
IX,
XI and
XII and rarely
von Willebrand factor (if causing a low factor VIII level) may lead to a prolonged aPTT correcting on mixing studies.
References